Skip to main content
SpringerLink
Log in

Cyclobarbital as a test substance for oxidative drug metabolism in man. Findings in neuropsychiatric patients

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The disappearance of cyclobarbital from plasma has been followed in healthy volunteers and in neurological and psychiatric patients after oral administration of one tablet of Phanodorm®, containing cyclobarbital calcium 200 mg. Plasma levels were measured by a thin-layer chromatographic method with in situ densitometry. The average t1/2 in healthy female and male volunteers was 13.3 h, and with the assumption of complete availability a mean distribution coefficient of 0.69 l/kg−1 and a clearance of 40.4 ml/min−1 were calculated. Repeated experiments in seven volunteers revealed good reproducibility of all values. When the healthy volunteers were combined with a group of untreated epileptics, a dependence of t1/2 and of the apparent volume of distribution on age was found, while clearance did not change with increasing age (range 17–54 years). Long half-lives caused by low clearance values were observed in several individuals with moderate obesity. No consistent change in cyclobarbital kinetics followed acute exposure of volunteers to alcohol or on treatment of neurological patients with carbamazepine. Patients under treatment with perazine exhibited more or less normal kinetic values. In terms of drug interaction, cyclobarbital differs from phenazone in several respects, and so it may prove a useful additional substance for measurement of the rate of drug oxidation in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andreasen, P.B., Vesell, E.S.: Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin. Pharmacol. Ther.16, 1059–1065 (1974)

    Google Scholar 

  • Arnold, W., Grützmacher, H.F.: Die Identifizierung von Barbiturat-Metaboliten mittels Massenspektrometrie und Infrarot-Spektrum. Arch. Toxikol.25, 200–215 (1969)

    Google Scholar 

  • Breimer, D.D., Winten, M.A.C.M.: Pharmacokinetics and relative bioavailability of cyclobarbital calcium in man after oral administration. Europ. J. clin. Pharmacol.9, 443–450 (1976)

    Google Scholar 

  • Breyer, U.: Perazine, chlorpromazine and imipramine as inducers of microsomal drug metabolism. Naunyn-Schmiedeberg's Arch. Pharmacol.272, 277–288 (1972)

    Google Scholar 

  • Breyer, U.: Rapid and accurate determination of the level of carbamazepine in serum by ultraviolet reflectance photometry on thin-layer chromatograms. J. Chromatogr.108, 370–374 (1975)

    Google Scholar 

  • Breyer, U., Jahns, I., Irmscher, G., Rassner, H., Rehmer, S.: Kinetics of35S-perazine in the bile fistula rat. Naunyn-Schmiedeberg's Arch. Pharmacol.300, 47–56 (1977)

    Google Scholar 

  • Breyer, U., Villumsen, D.: Thin-layer chromatographic determination of barbiturates and phenytoin in serum and blood. J. Chromatogr.115, 493–500 (1975)

    Google Scholar 

  • Breyer, U., Villumsen, K.: Measurement of plasma levels of tricyclic psychoactive drugs and their metabolites by UV reflectance photometry of thin layer chromatograms. Europ. J. clin. Pharmacol.9, 457–465 (1976)

    Google Scholar 

  • Bush, M.T., Weller, W.L.: Metabolic fate of hexobarbital (HB). Drug Metab. Rev.1, 249–290 (1972)

    Google Scholar 

  • Chung, H., Brown, D.R.: Mechanism of the effect of acute ethanol on hexobarbital metabolism. Biochem. Pharmacol.25, 1613–1616 (1976)

    Google Scholar 

  • Cinti, D.L., Grundin, R., Orrenius, S.: The effect of ethanol on drug oxidations in vitro and the significance of ethanol-cytochrome P-450 interaction. Biochem. J.134, 367–375 (1973)

    Google Scholar 

  • Crooks, J., O'Malley, K., Stevenson, I.H.: Pharmacokinetics in the elderly. Clin. Pharmacokin.1, 280–296 (1976)

    Google Scholar 

  • Ehrnebo, M., Agurell, S., Jalling, B., Boréus, L.O.: Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults. Europ. J. clin. Pharmacol.3, 189–193 (1971)

    Google Scholar 

  • Ehrnebo, M., Odar-Cederlöf, I.: Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients. Europ. J. clin. Pharmacol.8, 445–453 (1975)

    Google Scholar 

  • Fretwurst, F., Halberkann, J., Reiche, F.: Phanodorm und seine Wiederausscheidung mit dem Harn. Münch. med. Wochenschr.79, 1429–1432 (1932)

    Google Scholar 

  • Gibaldi, M., Boyes, R. N., Feldman, S.: Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci.60, 1338–1340 (1971)

    Google Scholar 

  • Gundert-Remy, U., Marquardt, R., Andritsch, F., Weber, E.: Veränderungen der Halbwertszeit von Antipyrin und Tolbutamid bei chronischen Alkoholikern im Verlauf der Entziehungstherapie. Inn. Med.2, 67–72 (1975)

    Google Scholar 

  • Haacke, H., Johnsen, K., Kolenda, K.-D.: Interaction of pentobarbital, diphenylhydantoin and digitoxin with ethanol in isolated perfused guinea-pig liver. Arzneim.-Forsch.26, 835–839 (1976)

    Google Scholar 

  • Hepner, G. W., Vesell, E. S., Lipton, A., Harvey, H. A., Wilkinson, G. R., Schenker, S.: Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: Diazepam breath test and correlations in drug elimination. J. Lab. Clin. Med.90, 440–456 (1977)

    Google Scholar 

  • Hvidberg, E. F., Dam, M.: Clinical pharmacokinetics of anticonvulsants. Clin. Pharmacokin.1, 161–188 (1976)

    Google Scholar 

  • Iber, F. L.: Drug metabolism in heavy consumers of ethyl alcohol. Clin. Pharmacol. Ther.22, 735–742 (1977)

    Google Scholar 

  • Inaba, T., Kalow, W.: Salivary excretion of amobarbital in man. Clin. Pharmacol. Ther.18, 558–562 (1975)

    Google Scholar 

  • Inaba, T., Tang, B. K., Endrenyi, L., Kalow, W.: Amobarbital — probe of hepatic drug oxidation in man. Clin. Pharmacol. Ther.20, 439–444 (1976)

    Google Scholar 

  • Irvine, R. E., Grove, J., Toseland, P. A., Trounce, J. R.: The effect of age on the hydroxylation of amylobarbitone sodium in man. Br. J. clin. Pharmacol.1, 41–43 (1974)

    Google Scholar 

  • Janke, W., Schmatzer, E.: Experimental-psychologische Untersuchungen zur Wirkung einer Prothipendyl-Cyclobarbital-Calcium-Kombination im Vergleich zu Cyclobarbital-Calcium und Placebo. Arzneim.-Forsch.12, 1031–1036 (1962)

    Google Scholar 

  • Kadar, D., Inaba, T., Endrenyi, L., Johnson, G. E., Kalow, W.: Comparative drug elimination capacity in man — glutethimide, amobarbital, antipyrine, and sulfinpyrazone. Clin. Pharmacol. Ther.14, 552–560 (1973)

    Google Scholar 

  • Klotz, U., Avant, G. R., Hoyumpa, A., Schenker, S., Wilkinson, G. R.: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J. clin. Invest.55, 347–359 (1975)

    Google Scholar 

  • Leslie, C. A., Gottesfeld, Z., Elliott, A. C.: Effect of ethanol on entry of some substances into the brain of rats. Canad. J. Physiol. Pharmacol.49, 833–840 (1971)

    Google Scholar 

  • Lieber, C. S., Teschke, R., Hasumura, Y., DeCarli, L. M.: Differences in hepatic and metabolic changes after acute and chronic alcohol consumption. Fed. Proc.34, 2060–2074 (1975)

    Google Scholar 

  • Machata, G.: Über die gaschromatographische Blutalkoholbestimmung. 2. Mitteilung. Blutalkohol7, 345–348 (1970)

    Google Scholar 

  • Münch, F. L.: Enzymkinetische Untersuchungen zur mikrosomalen Barbiturat-Hydroxylierung und ihrer Hemmbarkeit durch Äthanol. Thesis, Universität Tübingen 1978

  • Petruch, F., Schüppel, R. V. A.: Einfluß antikonvulsiver Behandlung auf den Arzneimittelabbau beim Menschen. Induktion des hydroxylierenden Enzymsystems der Leber durch Diphenylhydantoin und Carbamazepin. Bibl. Psychiatr.151, 76–80 (1975)

    Google Scholar 

  • Petruch, F., Schüppel, R., Breyer, U.: Änderung des Arzneimittelabbaus in der Leber unter der Behandlung mit Perazin. Arzneim.-Forsch.26, 1154–1155 (1976)

    Google Scholar 

  • Pirttiaho, H. I., Sotaniemi, E. A., Ahlqvist, J., Pitkänen, U., Pelkonen, R. O.: Liver size and indices of drug metabolism in alcoholics. Eur. J. clin. Pharmacol.13, 61–67 (1978)

    Google Scholar 

  • Reidenberg, M. M.: Obesity and fasting — effects on drug metabolism and drug action in man. Clin. Pharmacol. Ther.22, 729–734 (1977)

    Google Scholar 

  • Rubin, E., Gang, H., Misra, P. S., Lieber, C. S.: Inhibition of drug metabolism by acute alcohol intoxication. A hepatic microsomal metabolism. Am. J. Med.49, 801–806 (1970)

    Google Scholar 

  • Sachs, L.: Statistische Auswertungsmethoden. Berlin, Heidelberg, New York: Springer 1968

    Google Scholar 

  • Schüppel, R. V. A.: Drug metabolism as influenced by ethanol. Pharmacokinetic aspects of drug-ethanol interaction. Excerpta Medica, Int. Congr. Ser.254, 52–62 (1972)

    Google Scholar 

  • Schüppel, R., Petruch, F.: Mechanism of barbiturate-ethanol interaction. Naunyn-Schmiedeberg's Arch. Pharmacol.270, R129 (1971)

  • Seidel, G.: Verteilung von Pentobarbital, Barbital und Thiopental unter Äthanol. Naunyn-Schmiedeberg's Arch. exp. Pathol. Pharmakol.257, 221–229 (1967)

    Google Scholar 

  • Smith, S. E., Rawlins, M. D.: Prediction of drug oxidation rates in man: Lack of correlation with serum gamma-glutamyl trans-peptidase and urinary excretion of D-glucaric acid and 6β-hydroxy cortisol. Eur. J. clin. Pharmacol.7, 71–75 (1974)

    Google Scholar 

  • Thomas, B. H., Coldwell, B. B., Solomouraj, G., Zeitz, W., Trenholm, H. L.: Effect of ethanol on the fate of pentobarbital in the rat. Biochem. Pharmacol.21, 2605–2614 (1972)

    Google Scholar 

  • Tilstone, W. J., Reavey, P. C.: Ethanol and the disposition of amylobarbitone: effect of dose and significance as a mechanism for increased toxicity. J. Pharm. Pharmacol.30, 319–320 (1978)

    Google Scholar 

  • Vajda, F., Williams, F. M., Davidson, S., Falconer, M. A., Brekkenridge, A.: Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin. Pharmacol. Ther.15, 597–603 (1974)

    Google Scholar 

  • Vesell, E. S., Page, J. G.: Genetic control of dicumarol levels in man. J. clin. Invest.47, 2657–2663 (1968)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Toxikologie der Universität Tübingen, Federal Republic of Germany

    U. Breyer-Pfaff & H. Jerg

  2. Neurologische Klinik, Abteilung Allgemeine Neurologie, Universität Tübingen, Federal Republic of Germany

    F. Petruch

Authors
  1. U. Breyer-Pfaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Jerg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Petruch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breyer-Pfaff, U., Jerg, H. & Petruch, F. Cyclobarbital as a test substance for oxidative drug metabolism in man. Findings in neuropsychiatric patients. Eur J Clin Pharmacol 15, 433–441 (1979). https://doi.org/10.1007/BF00561744

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00561744

Key words

Search

Navigation